

CITATION REPORT

List of articles citing

A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer

DOI: 10.2217/fon-2022-0310
Future Oncology, , , .

Source: <https://exaly.com/paper-pdf/146044208/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.		0
3	Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. 2022 ,		1
2	Diagnostic quality model (DQM): an integrated framework for the assessment of diagnostic quality when using AI/ML. 2023 , 61, 544-557		0
1	Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence. 2023 , 18, 287-294		0